A strategic shift to a license partnership model has driven profitability and growth, with validated infection-prevention technology and major partnerships fueling expansion. Targets for 2030 include SEK 600 million in revenue, with strong momentum in wound management and new therapeutic areas.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.